Rapid immunodiagnostic tests serve settings from hospital labs to home use, but most still rely on conventional antibody detection. This report maps the emerging alternatives—nanobodies, aptamers, CRISPR-based detection and other binding platforms—and assesses which are ready for real-world deployment and which remain research tools.
Three pages from this report, open in full. The rest opens when you own it.
Seven parts, the same tabs you get when you own the report.
5 use cases
The technology recommended for each, with the alternatives.
+ 2 more
5 classes
Every class compared, with its patent trend and leading players.
+ 2 more
6 sectors
Mapped against the classes, with who sits in each.
Published November 2026 · © 2026 Berkeley FIT LLC. All rights reserved.
+ 3 more
484 companies
Searchable and filterable by sector, class and relevance.
+ 481 more
986 patents
Dominant and emerging holders for each mechanism of action.
+ 7 more
4 pathways
What each means for timelines and cost.
1 catalog
Take the data with you.